# EDGAR Filing Document

**Accession Number:** 0001628908
**File Stem:** 0001628908-26-000037
**Filing Date:** 2026-6
**Character Count:** 7436
**Document Hash:** b46c5b9fc827bfc83e706750c03010b1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628908-26-000037.hdr.sgml**: 20260604

**ACCESSION NUMBER**: 0001628908-26-000037

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260604

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260604

**DATE AS OF CHANGE**: 20260604

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evolent Health, Inc.
- **CENTRAL INDEX KEY:** 0001628908
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MANAGEMENT SERVICES [8741]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 320454912
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37415
- **FILM NUMBER:** 261064884

**BUSINESS ADDRESS:**
- **STREET 1:** 1812 NORTH MOORE ST, SUITE 1705
- **CITY:** ARLINGTON
- **STATE:** VA
- **ZIP:** 22209
- **BUSINESS PHONE:** 571-389-6000

**MAIL ADDRESS:**
- **STREET 1:** 1812 NORTH MOORE ST, SUITE 1705
- **CITY:** ARLINGTON
- **STATE:** VA
- **ZIP:** 22209

?xml version='1.0' encoding='ASCII'? evh-20260604

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**_________________________**

**FORM 8-K**

**_________________________**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

June 4, 2026

Date of Report (Date of earliest event reported)

**Evolent Health, Inc.** 

(Exact name of registrant as specified in its charter)

**_________________________**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Delaware** | | **001-37415** | **001-37415** | **001-37415** | **001-37415** | **001-37415** | | **32-0454912** |
| (State or other jurisdiction of incorporation or organization) |  | Commission File Number: | Commission File Number: | Commission File Number: | Commission File Number: | Commission File Number: |  | (I.R.S. Employer<br>Identification No.) |
| **1812 N. Moore Street** | **,** | **Suite 1705** | **,** | **Arlington** | **,** | **Virginia** | **,** | **22209** |
| (Address of principal executive offices)(zip code) | (Address of principal executive offices)(zip code) | (Address of principal executive offices)(zip code) | (Address of principal executive offices)(zip code) | (Address of principal executive offices)(zip code) | (Address of principal executive offices)(zip code) | (Address of principal executive offices)(zip code) | (Address of principal executive offices)(zip code) | (Address of principal executive offices)(zip code) |

---

**<u>(571) 389-6000</u>**

(Registrant's telephone number, including area code)

**<u>Not Applicable</u>**

(Former name, former address and former fiscal year, if changed since last report.)

_________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Class A Common Stock of Evolent Health, Inc., par value $0.01 per share | EVH | New York Stock Exchange |

---

------

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

------

**Item 5.07 Submission of Matters to a Vote of Security Holders** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) &nbsp;&nbsp;&nbsp;&nbsp;Evolent Health, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") on June 4, 2026. At the 2026 Annual Meeting, the Company's stockholders voted on four proposals. The proposals are described in the Company's definitive proxy statement on Schedule 14A for the 2026 Annual Meeting filed with the Securities and Exchange Commission on April 24, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &nbsp;&nbsp;&nbsp;&nbsp;The final voting results with respect to each proposal voted upon at the 2026 Annual Meeting are set forth below.

**<u>Proposal 1</u>**

The Company's stockholders elected ten director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified, as set forth below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For** | **Against** | **Abstentions** | **Broker <br>Non-Votes** |
| Toyin Ajayi, MD | 60373601 | 5912292 | 90502 | 15840303 |
| Craig Barbarosh | 65818775 | 467147 | 90471 | 15840305 |
| Seth Blackley | 60323961 | 5993625 | 58810 | 15840302 |
| Russell Glass | 60316659 | 5982067 | 77670 | 15840302 |
| Peter Grua | 60324441 | 5961459 | 90496 | 15840302 |
| Shawn Guertin | 65881893 | 396849 | 97653 | 15840303 |
| Richard Jelinek | 60027846 | 6269584 | 78965 | 15840303 |
| Kim Keck | 60178555 | 6131979 | 65860 | 15840304 |
| Jill Smith | 65919489 | 402133 | 54773 | 15840303 |
| Brendan Springstubb | 65810202 | 468292 | 97900 | 15840304 |

---

**<u>Proposal 2</u>**

The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 as set forth below:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstentions** |
| 82,036,843 | 124,362 | 55,493 |

---

**<u>Proposal 3</u>**

The Company's stockholders approved the compensation of our named executive officers for 2025 on an advisory basis, as set forth below:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstentions** | **Broker<br>Non-Votes** |
| 58,369,473 | 7,922,802 | 84,119 | 15,840,304 |

---

**<u>Proposal 4</u>**

------

The Company's stockholders approved the amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan, as set forth below:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstentions** | **Broker<br>Non-Votes** |
| 47,536,873 | 18,712,636 | 126,885 | 15,840,304 |

---

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| | Evolent Health, Inc. |
| Date: June 4, 2026 | /s/ Jonathan D. Weinberg |
| | Jonathan D. Weinberg |
| | *General Counsel and Secretary* |

---